The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills
Abstract
Estrogen and progestins have been used by millions of women as effective combined oral contraceptives. Oral contraceptives (OCs) modify surrogate markers such as lipoproteins, insulin response to glucose, and coagulation factors, that have been associated with cardiovascular and venous risk. Ethinyl-Estradiol (EE) exerts a stronger effect that natural estradiol (E2) on hepatic metabolism. New progestins with high specificity have been designed to avoid interaction with other receptors and prevent androgenic, estrogenic or glucocorticoid related side-effects. The risks and benefits of new progestins used in contraception depend upon their molecular structure, the type and dose of associated estrogen, and the delivery route. The lower impact of E2-based combinations on metabolic surrogate markers may result in an improved safety profile, but only clinical outcomes are relevant to assess the risk. Large surveillance studies are warranted to confirm this hypothesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Estrogens have a positive effect on lipid metabolism, increasing HDL-C and decreasing LDL-C, while progestins, depending on their type and androgenicity, may counteract these positive estrogenic effects [23-25] .”
From Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone (2021) · cites this paper as [25]
Citations
Cites
National Center for Health Statistics (NCHS)
Feinleib, M. (2005) · Encyclopedia of Biostatistics · doi:10.1002/0470011815.b2a16042 · Cited by 3,134
Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.
Guilherme, A., Virbasius, J. V., Puri, V., & Czech, M. P. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2391 · Cited by 2,292
Heit, J. A., Kobbervig, C. E., James, A., Petterson, T. M., Bailey, K. R., & Melton, L. J. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-10-200511150-00006 · Cited by 1,336
Chandra, A., Martinez, G. M., Mosher, W. D., Abma, J. C., & Jones, J. (2005) · PsycEXTRA Dataset · doi:10.1037/e414702008-001 · Cited by 957
Classification and pharmacology of progestins
Schindler, A. E., Campagnoli, C., Druckmann, R. A., Huber, J. C., Pasqualini, J. R., Schweppe, K.-W., & Thijssen, J. H. H. (2003) · Maturitas · doi:10.1016/j.maturitas.2003.09.014 · Cited by 741
Lidegaard, O., Nielsen, L. H., Skovlund, C. W., Skjeldestad, F. E., & Lokkegaard, E. (2011) · BMJ · doi:10.1136/bmj.d6423 · Cited by 608
Dinger, J. C., Heinemann, L. A. J., & Kühl-Habich, D. (2007) · Contraception · doi:10.1016/j.contraception.2006.12.019 · Cited by 472
Godsland, I. F., Crook, D., Simpson, R., Proudler, T., Felton, C., Lees, B., Anyaoku, V., Devenport, M., & Wynn, V. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011153232003 · Cited by 417
Mellick, R. S., Mahler, R., & Hughes, B. P. (1962) · The Lancet · doi:10.1016/s0140-6736(62)92145-1 · Cited by 390
Factors Associated with Contraceptive Choice and Inconsistent Method Use, United States, 2004
Frost, J. J., & Darroch, J. E. (2008) · Perspectives on Sexual and Reproductive Health · doi:10.1363/4009408 · Cited by 381
Research works printed but not linked: 1
- Parke, 2008, Oral comparative effects of a four-phasic regimen of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel on haemostatic parameters, Human Reproduction, 23, i77
Cited by
Sorted by citations
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
“A controlled feeding study conducted by Maki et al.56 evaluated the effects of a PUFA-rich corn oil and a MUFA-rich extra-virgin olive oil (4 tablespoons/day were incorporated into foods) as part of a weight maintenance diet (34% of energy from fat, w8% from saturated fatty acids) on lipids and lipoproteins in men and…”
BackgroundInfluentialThe polycystic ovary syndrome: a position statement from the European Society of Endocrinology
Conway, G., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Franks, S., Gambineri, A., Kelestimur, F., Macut, D., Micic, D., Pasquali, R., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0253 · Cited by 676
Sex differences in lipids: a life course approach
Holven, K. B., & Roeters van Lennep, J. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117270 · Cited by 180
Treatment strategies for women with polycystic ovary syndrome
Jin, P., & Xie, Y. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1395841 · Cited by 181
“Some studies have found that ethinylestradiol has stronger effects on liver metabolism than natural estradiol, including the synthesis of SHBG, angiotensin, and some blood coagulation factors dependent on estrogen [22].”
BackgroundCross-Sex Hormonal Treatment and Body Uneasiness in Individuals with Gender Dysphoria
Fisher, A. D., Castellini, G., Bandini, E., Casale, H., Fanni, E., Benni, L., Ferruccio, N., Meriggiola, M. C., Manieri, C., Gualerzi, A., et al. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12413 · Cited by 147
Combined hormonal contraceptives: prescribing patterns, compliance, and benefits versus risks
Brynhildsen, J. (2014) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098614548857 · Cited by 143
“…the ethinyl group also changes the properties of the molecule making EE far more potent than E2 as EE does not bind to sex hormone-binding globulin (SHBG), is resistant to enzymatic degradation by 17-beta-hydroxylas and has a higher affinity for the estrogen receptor [Sitruk-Ware and Nath, 2013].”
BackgroundGooren, L. J., Wierckx, K., & Giltay, E. J. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0011 · Cited by 136
Asscheman, H., T'Sjoen, G. G., Lemaire, A., Mas, M., Meriggiola, M. C., Mueller, A., Kühn, A., Dhejne, C., Morel-Journel, N., & Gooren, L. J. (2013) · Andrologia · doi:10.1111/and.12150 · Cited by 133
“The prothrombotic effect of ethinyl oestradiol was ascribed to its molecular structure rather than to the first-pass liver effect which ethinyl oestradiol shares with all other types of oral oestrogens (Toorians et al., 2003; Sitruk-Ware & Nath, 2013).”
BackgroundEffects of hormonal contraception on systemic metabolism: cross-sectional and longitudinal evidence
Wang, Q., Würtz, P., Auro, K., Morin-Papunen, L., Kangas, A. J., Soininen, P., Tiainen, M., Tynkkynen, T., Joensuu, A., Havulinna, A. S., et al. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw147 · Cited by 117
A Review on Sex Steroid Hormone Estrogen Receptors in Mammals and Fish
Amenyogbe, E., Chen, G., Wang, Z., Lü, X., Mingde, L., & Lin, A. Y. (2020) · International Journal of Endocrinology · doi:10.1155/2020/5386193 · Cited by 113
Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone
Klipping, C., Duijkers, I., Mawet, M., Maillard, C., Bastidas, A., Jost, M., & Foidart, J.-M. (2021) · Contraception · doi:10.1016/j.contraception.2021.01.001 · Cited by 108
A systematic review of the impact of oral contraceptives on cognition
Warren, A. M., Gurvich, C., Worsley, R., & Kulkarni, J. (2014) · Contraception · doi:10.1016/j.contraception.2014.03.015 · Cited by 117
“The most commonly used estrogen analogue is ethinylestradiol [3], though recent innovation has seen the introduction of physiological forms of estrogen such as estradiol and estradiol valerate [4,5].”
BackgroundRole of Oxidative Stress in Obese and Nonobese PCOS Patients
Uçkan, K., Demir, H., Turan, K., Sarıkaya, E., & Demir, C. (2022) · International Journal of Clinical Practice · doi:10.1155/2022/4579831 · Cited by 97
“New generation endogenous estrogens, such as dienogest [47], 17-estradiol, estradiol valerate, and estetrol [48] reduce the risk of treatment.”
Approach to the Patient: Contraception in Women With Polycystic Ovary Syndrome
Yıldız, B. O. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3196 · Cited by 90
“Most of these side effects lessen significantly after the first few months of use (8).”
BackgroundInfluentialTaylor, C. M., Pritschet, L., & Jacobs, E. G. (2020) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2020.100874 · Cited by 93
“Almost all consist of a combination of two synthetic sex hormones, ethinyl estradiol and progestin, that act predominantly on endogenous sex steroid hormone receptors (Louw-du Toit et al., 2017; Sitruk-Ware and Nath, 2013).”
BackgroundMECHANISMS IN ENDOCRINOLOGY: Epidemiology of hormonal contraceptives-related venous thromboembolism
Hugon‐Rodin, J., Gompel, A., & Plu‐Bureau, G. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0527 · Cited by 80
Orlando, E. F., & Ellestad, L. E. (2014) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2014.03.038 · Cited by 81
An Update on Contraception in Polycystic Ovary Syndrome
Oguz, S. H., & Yildiz, B. O. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.958 · Cited by 76
“EE use leads to increased synthesis of liver proteins including lipoproteins, angiotensinogen, and estrogen-dependent clotting factors [9], which are associated with the main adverse events attributed to COCs.”
BackgroundInfluentialBethea, T. N., Rosenberg, L. A., Hong, C., Troester, M. A., Lunetta, K. L., Bandera, E. V., Schedin, P. S., Kolonel, L. N., Olshan, A. F., Ambrosone, C. B., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0535-x · Cited by 74
“The estrogen and progestin composition of OCs has varied, with declining doses of hormones and new types of progestin introduced over time [40,60,61].”
BackgroundInteractions between Food and Drugs, and Nutritional Status in Renal Patients: A Narrative Review
D’Alessandro, C., Benedetti, A., Di Paolo, A., Giannese, D., & Cupisti, A. (2022) · Nutrients · doi:10.3390/nu14010212 · Cited by 66
“Steroidal anti-inflammatory drugs, estrogen-progestin preparations and antidiabetic drugs (both oral and injectable ones) affect glucose and/or fat metabolism [28].”
BackgroundEllestad, L. E., Cardon, M. C., Chambers, I. G., Farmer, J., Hartig, P. C., Stevens, K. E., Villeneuve, D. L., Wilson, V. S., & Orlando, E. F. (2014) · Environmental Science & Technology · doi:10.1021/es501428u · Cited by 65
Luque-Ramírez, M., Nattero-Chávez, L., Ortiz Flores, A. E., & Escobar-Morreale, H. F. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmx039 · Cited by 62
Cauci, S., Xodo, S., Buligan, C., Colannino, C., Barbina, M., Barbina, G., & Francescato, M. P. (2021) · Molecules · doi:10.3390/molecules26041070 · Cited by 61
“Abbreviations BMI Body mass index CI Confidence interval CVD Cardiovascular disease FORT Free oxygen radical test hsCRP High-sensitivity C-reactive protein IQR Interquartile range: from 25th to 75th percentile NF-kB Nuclear factor kappa-light-chain-enhancer of activated B cells Nrf2 Nuclear erytroid 2-like factor-2 OC…”
BackgroundInfluentialNokoff, N., Scarbro, S. L., Moreau, K. L., Zeitler, P. S., Nadeau, K. J., Juarez‐Colunga, E., & Kelsey, M. M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz029 · Cited by 58
Priest, S. E., Shenouda, N., & MacDonald, M. J. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00039.2018 · Cited by 56
Hampson, E. (2022) · Frontiers in neuroendocrinology (Print) · doi:10.1016/j.yfrne.2022.101040 · Cited by 46
Agarwala, A., Dixon, D. L., Gianos, E., Kirkpatrick, C. F., Michos, E. D., Satish, P., Birtcher, K. K., Braun, L. T., Pillai, P., Watson, K., et al. (2024) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.05.005 · Cited by 57
Effects of oral contraceptives on metabolic parameters in adult premenopausal women: a meta-analysis
Silva-Bermudez, L. S., Toloza, F. J. K., Perez-Matos, M. C., de Souza, R. J., Banfield, L., Vargas-Villanueva, A., & Mendivil, C. O. (2020) · Endocrine Connections · doi:10.1530/ec-20-0423 · Cited by 52
“Even though in observational studies gestodene induced significant increases in HDLc (2), our study showed a numerically marginal increase.”
Cauci, S., Francescato, M. P., & Curcio, F. (2016) · Sports Medicine · doi:10.1007/s40279-016-0534-9 · Cited by 49
“Additionally, we observed slightly reduced concentrations of alkaline phosphatase in OC users, this is likely due to the reduction of bone resorption produced by estrogens [39, 53].”
BackgroundResultInfluentialFrankel, T., Meyer, M. T., & Orlando, E. F. (2016) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2016.01.007 · Cited by 47
Kotamarti, V. S., Greige, N., Heiman, A. J., Patel, A., & Ricci, J. A. (2021) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2021.04.006 · Cited by 45
Sood, M., Zweig, S. B., Tolentino, M. C., Strizhevsky, M., & Poretsky, L. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_33 · Cited by 43
Totaro, M., Palazzi, S., Castellini, C., Parisi, A., D’Amato, F., Tienforti, D., Baroni, M. G., Francavilla, S., & Barbonetti, A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.741866 · Cited by 43
Valentine, A., Davis, S., Furniss, A., Dowshen, N., Kazak, A. E., Lewis, C. S., Loeb, D. F., Nahata, L., Pyle, L. L., Schilling, L. M., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac469 · Cited by 42
Beltz, A. M. (2022) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2022.101037 · Cited by 41
Discontinuation of modern hormonal contraceptives: an Italian survey
Fruzzetti, F., Perini, D., Fornaciari, L., Russo, M., Bucci, F., & Gadducci, A. (2016) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/13625187.2016.1234598 · Cited by 38
Witjes, H., Creinin, M. D., Poromaa, I. S., Nguyen, A. M., & Korver, T. (2015) · The European Journal of Contraception & Reproductive Health Care · doi:10.3109/13625187.2015.1016154 · Cited by 37
Oxidative Stress in Female Athletes Using Combined Oral Contraceptives
Cauci, S., Buligan, C., Marangone, M., & Francescato, M. P. (2016) · Sports Medicine - Open · doi:10.1186/s40798-016-0064-x · Cited by 36
“Future studies are warranted to assess if the observed blood rise of oxidative stress associated with OC use is estrogens and/or progestin related [22, 24, 41].”
BackgroundInfluentialGenazzani, A. R., Fidecicchi, T., Arduini, D., Giannini, A., & Simoncini, T. (2023) · Gynecological Endocrinology · doi:10.1080/09513590.2023.2247093 · Cited by 35
“This capacity is lost from no-or anti-androgenic pro-gestins: this means that both the positive effect of estrogens on carbohydrate and lipid metabolism, and their stimulatory effects on coagulation factors are at their maximal expression with these pro-gestins [33].”
BackgroundSymptoms of mental disorders and oral contraception use: A systematic review and meta-analysis
Kraft, M. Z., Rojczyk, P., Weiß, T., Derntl, B., Kikinis, Z., Croy, I., & Heller, C. (2023) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2023.101111 · Cited by 38
The Effects of Hormonal Contraceptives on Glycemic Regulation
Cortés, M. E., & Alfaro, A. A. (2014) · The Linacre Quarterly · doi:10.1179/2050854914y.0000000023 · Cited by 33
Bisphenol A induces hepatic triglyceride level in adult male rare minnow Gobiocypris rarus
Mi, K., Chen, X., Lu, K., Zhu, Y., Zhang, M., Yang, H., Wei, W., & Zhang, Y. (2021) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2021.112050 · Cited by 34
Beyond a means of exposure: a new view of the mother in toxicology research
Catanese, M. C., Suvorov, A., & Vandenberg, L. N. (2014) · Toxicology Research · doi:10.1039/c4tx00119b · Cited by 34
Obesity and hormonal contraception: an overview and a clinician’s practical guide
Cipriani, S., Todisco, T., Scavello, I., Stasi, V. D., Maseroli, E., & Vignozzi, L. (2019) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-019-00774-w · Cited by 37
Mosorin, M., Haverinen, A., Ollila, M., Nordström, T., Jokelainen, J. J., Keinanen-Kiukaanniemi, S. M., Puukka, K. S., Ruokonen, A., AUVINEN, J. P., Piltonen, T., et al. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0406 · Cited by 33
Comparison of ESI– and APCI–LC–MS/MS methods: A case study of levonorgestrel in human plasma
Wang, R., Zhang, L., Zhang, Z., & Tian, Y. (2016) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2016.03.006 · Cited by 33
“As the use of oral contraceptives has increased globally, requirements of monitoring the pharmacokinetic behavior are gaining great importance [4].”
BackgroundOral contraceptives and cognition: A systematic review
Gurvich, C., Nicholls, I., Lavale, A., & Kulkarni, J. (2022) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2022.101052 · Cited by 38
Herrera, A. Y., Faude, S., Nielsen, S. E., Locke, M., & Mather, M. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100151 · Cited by 31
“Some reports indicate that levonorgestrel increases LDL levels (Kiley and Hammond, 2007; Knopp et al., 2001; Sitruk-Ware and Nath, 2011, 2013) and decreases HDL (Bergink et al., 1982; Gaspard et al., 1985; Godsland et al., 1990; Kaupplnen-Makelln et al., 1992; Kiley and Hammond, 2007; McGuire et al., 1990; Ruokonen an…”
InfluentialInfluence of an oral contraceptive containing drospirenone on insulin sensitivity of healthy women
Cagnacci, A., Piacenti, I., Zanin, R., Xholli, A., & Tirelli, A. (2014) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2014.03.021 · Cited by 28
“Indeed, it has been reported that OCs containing ethynil-estradiol (EE) associatedwith androgenic 2nd and 3rd generation progestins, lead to a reduction of SI [3,4].”
BackgroundThe effect of hormonal contraceptive therapy on clinical laboratory parameters: a literature review
Özcan, Ö., den Elzen, W. P. J., Hillebrand, J. J., den Heijer, M., van Loendersloot, L. L., Fischer, J., Hamer, H. M., de Jonge, R., & Heijboer, A. C. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-0384 · Cited by 35
“Although earlier progestins (norethindrone, MPA and CPA) could also affect metabolism [45], the latest progestin generations (NOMAC, DRSP and NES) essentially have no androgenic, estrogenic, or glucocorticoid-related adverse effects and no effects on fasting glucose or insulin levels [16, 43, 46].”
Romance, R., Vargas-Molina, S., Espinar, S., Petro, J. L., Bonilla, D. A., Schoenfeld, B. J., Kreider, R. B., & Benítez‐Porres, J. (2019) · International Journal of Sports Medicine · doi:10.1055/a-0985-4373 · Cited by 29
“This is an important limiting factor, since differences have been observed in the type of contraceptive (monophasic vs triphasic) and in the dose/progestin used [6, 28].”
BackgroundHirschberg, A. L. (2022) · Sports Medicine · doi:10.1007/s40279-021-01616-5 · Cited by 28
Paoletti, A. M., Cagnacci, A., Carlo, C. D., Orrù, M., Neri, M., D’Alterio, M. N., & Melis, G. B. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2014.1003294 · Cited by 26
Pharmacodynamics of combined estrogen-progestin oral contraceptives 3. Inhibition of ovulation
Bastianelli, C., Farris, M., Rosato, E., Brosens, I. A., & Benagiano, G. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1536544 · Cited by 26
“The well-known adverse effects of EE in COCs led to exploring the use of the natural hormone, estradiol-17β, because the use of natural estrogens has been hailed as capable of improving safety of COC with documented metabolic advantages [69].”
BackgroundPalacios, S., Colli, E., & Regidor, P. (2021) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/13625187.2021.1957094 · Cited by 25
“Depending on their pharmacological properties, they may counteract these positive oestrogenic effects [6,22,36]: COCs with a more androgenic progestin, such as LNG, show a decrease in HDL-cholesterol and an increase in LDL-Cholesterol, while COCs with rather anti-androgenic activity, such as DRSP, were shown to have a…”
BackgroundTailored hormonal approach in women with premature ovarian insufficiency
Fruzzetti, F., Palla, G., Gambacciani, M., & Simoncini, T. (2019) · Climacteric · doi:10.1080/13697137.2019.1632284 · Cited by 24
The benefits of estetrol addition to drospirenone for contraception
Foidart, J. M., Gemzell‐Danielsson, K., Kubba, A., Douxfils, J., Creinin, M. D., & GASPARD, U. J. (2023) · AJOG Global Reports · doi:10.1016/j.xagr.2023.100266 · Cited by 23
Kangasniemi, M. H., Haverinen, A., Luiro, K., Hiltunen, J. K., Komsi, E. K., Arffman, R. K., Heikinheimo, O., Tapanainen, J. S., & Piltonen, T. T. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa186 · Cited by 22
Casto, K. V., Jordan, T. R., & Petersen, N. (2022) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2022.101036 · Cited by 24
“As a result, OC use significantly inhibits hypothalamic-pituitary-ovarian activity, effectively reducing overall serum levels of endogenous progesterone and estradiol (Porcu et al., 2019; Rapkin et al., 2006; Sitruk-Ware & Nath, 2013).”
BackgroundCho, B., Heo, J. W., Shin, J. P., Ahn, J., Kim, T. W., & Chung, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102816 · Cited by 21
“OCP increase the levels of prothrombin fragments, fibrinogen, plasmin–antiplasmin complex, and protein C activity, and decrease antithrombin activity and the level of tissue-plasminogen activator [27,28].”
BackgroundUsselman, C. W., Nielson, C. A., Luchyshyn, T. A., Gimon, T. I., Coverdale, N. S., Uum, S. H. M. V., & Shoemaker, J. K. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00190.2016 · Cited by 20
“The effects of synthetic estrogens, such as those in HCs, may be stronger than those exerted by endogenous estradiol (44), indicating a potential mechanism by which vascular reactivity may be more impaired in women using HCs relative to women in the ML phase of the menstrual cycle.”
L-glutamine ameliorates adipose-hepatic dysmetabolism in OC-treated female rats
Olaniyi, K. S., & Olatunji, L. A. (2020) · Journal of Endocrinology · doi:10.1530/joe-19-0582 · Cited by 20
Heterogeneous Circulating Angiogenic Cell Responses to Acute Maximal Exercise
Shill, D. D., Marshburn, M. P., Hempel, H. K., Lansford, K. A., & Jenkins, N. T. (2016) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000001029 · Cited by 18
“Synthetic sex hormone-based contraceptive therapies maintain low concentrations of endogenous estrogen and progesterone throughout the menstrual cycle, and have been shown to alter metabolism, hemostasis, and vascular function (6,32).”
BackgroundKangasniemi, M. H., Arffman, R. K., Joenväärä, S., Haverinen, A., Luiro, K., Tohmola, T., Renkonen, R., Heikinheimo, O., Tapanainen, J. S., & Piltonen, T. T. (2023) · Human Reproduction · doi:10.1093/humrep/deac250 · Cited by 19
“As the progestin component of COCs modulates the estrogen effects, the net effect of a COC depends on both the type of estrogen and the properties of the progestin (Sitruk-Ware and Nath, 2013; Abou-Ismail et al., 2020).”
BackgroundInfluentialHormonal contraceptives as disruptors of competitive behavior: Theoretical framing and review
Arthur, L. C., Casto, K. V., & Blake, K. R. (2022) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2022.101015 · Cited by 20
ADVERSE EFFECT OF COMBINED ORAL CONTRACEPTIVE PILLS
Shukla, A., Jamwal, R., & Bala, K. (2016) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2017.v10i1.14565 · Cited by 18
“Besides, progestin-only contraceptive pills are a contraceptive method that may be the better option for women with several routes of administration are available these days [6].”
BackgroundHaverinen, A., Kangasniemi, M., Luiro, K., Piltonen, T., Heikinheimo, O., & Tapanainen, J. S. (2021) · Contraception · doi:10.1016/j.contraception.2020.10.014 · Cited by 17
Hampson, E., Morley, E. E., Evans, K. L., & Fleury, C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.888510 · Cited by 17
“The estrane- and early gonane-based OCs used in Study 1 have stronger androgenic effects in vivo (but often contain higher doses of EE2) than many OCs based on 3 or 4 generation progestins (10, 66), some of which have anti-androgen effects at concentrations used therapeutically (e.”
BackgroundOestrogens in oral contraception: considerations for tailoring prescription to women’s needs
Fruzzetti, F., Fidecicchi, T., & Gambacciani, M. (2024) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/13625187.2024.2334350 · Cited by 18
Hormonal Contraception and the Brain: Examining Cognition and Psychiatric Disorders
Laird, S., Ney, L. J., Felmingham, K. L., & Gogos, A. (2019) · Current Psychiatry Research and Reviews · doi:10.2174/1573400515666190521113841 · Cited by 19
Allaway, H. C. M., Misra, M., Ricker, E. A., Stone, M. S., Weaver, C. M., Petkus, D. L., & Souza, M. J. D. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00334 · Cited by 16
“However, COC use may result in reduced hepatic IGF-I synthesis in young women (18, 19), likely due to the “first pass effect,” by which EEmetabolism in the liver decreases hepatic synthesis of IGF-I (20).”
BackgroundShiferaw, M., Kassahun, W. D., & Zawdie, B. (2021) · BMC Women s Health · doi:10.1186/s12905-021-01178-8 · Cited by 16
Chantrapanichkul, P., Indhavivadhana, S., Wongwananuruk, T., Techatraisak, K., Dangrat, C., & Sa‐nga‐areekul, N. (2020) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-019-05423-2 · Cited by 16
Diamanti‐Kandarakis, E., Duntas, L. H., Kanakis, G., Kandaraki, E., Karavitaki, N., Kassi, E. N., Livadas, S., Mastorakos, G. P., Migdalis, I. N., Miras, A. D., et al. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0154 · Cited by 15
Can We Measure the Individual Prothrombotic or Prohemorrhagic Tendency by Global Coagulation Tests?
Reda, S., Morimont, L., Douxfils, J., & Rühl, H. (2020) · Hämostaseologie · doi:10.1055/a-1153-5824 · Cited by 17
Brazilian Guideline on Menopausal Cardiovascular Health – 2024
de Oliveira, G. M. M., de Almeida, M. C. C., Artucio, C., Espíndola, L. N., Rivera, M. A. M., Filho, A. L. D. S., Marques-Santos, C., Fernandes, C. E., Albuquerque, C. J. D. M., Freire, C. M. V., et al. (2024) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240478i · Cited by 17
Fait, T., Buryak, D., Cirstoiu, M.-M., Luczai, E., & Janczura, R. (2018) · Drugs in Context · doi:10.7573/dic.212510 · Cited by 14
Alopecia due to high androgen index contraceptives
Graves, K. Y., Smith, B. J., & Nuccio, B. C. (2018) · JAAPA · doi:10.1097/01.jaa.0000541476.24116.c4 · Cited by 13
Li, C., Xie, Y., Li, Z., Yang, M., Sun, X., Fan, J., Zhu, H. Y. X., Wang, C., & Li, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112499 · Cited by 13
“We speculate that the reason for this may be the consumption during menstruation and the relatively low level of sex hormone during menstruation, since oral estrogen increases fibrinogen concentration in blood [41, 42].”
BackgroundKrysiak, R. G., Szkróbka, W., & Okopień, B. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0921-6420 · Cited by 13
Swanepoel, A. C., Bester, J., Emmerson, O., Soma, P., Beukes, D., van Reenen, M., Loots, D. T., & du Preez, I. (2020) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2020.0009 · Cited by 13
“…synthesis to a greater extent than some of the natural estrogens and can induce powerful stimulation of liver proteins and coagulation factors especially when combined with an anti-androgenic progestin, such as DRSP, which cannot fully counteract the effects of EE (Sitruk-Ware and Nath, 2013).”
Jensen, J. T., Bitzer, J., Nappi, R. E., Ahlers, C., Bannemerschult, R., & Parke, S. (2020) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/13625187.2020.1731734 · Cited by 12
Herbal supplements interactions with oral oestrogen‐based contraceptive metabolism and transport
Hlengwa, N., Muller, C. J. F., Basson, A. K., Bowles, S., Louw, J., & Awortwe, C. (2020) · Phytotherapy Research · doi:10.1002/ptr.6623 · Cited by 13
“This led to structural modification in the synthesis of the steroid hormones that did not exert these secondary unwanted effects (Sitruk-Ware & Nath, 2013).”
BackgroundLuque‐Ramírez, M., Ortiz-Flores, A. E., Nattero‐Chávez, L., & Escobar-Morreale, H. F. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1839409 · Cited by 11
Kaur, H., Bala, M., & Bansal, G. (2018) · Environmental Science and Pollution Research · doi:10.1007/s11356-018-2754-z · Cited by 11
Reproductive factors, genetic susceptibility and risk of type 2 diabetes: A prospective cohort study
Fan, G., Liu, Q., Bi, J., Qin, X., Fang, Q., Luo, F., Huang, X., Li, H., Wang, Y., & Song, L. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101560 · Cited by 10
Olaniyi, K. S., Sabinari, I. W., & Olatunji, L. A. (2019) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2019.103305 · Cited by 11
Use of contraception before and after a diabetes diagnosis: An observational matched cohort study
Horwitz, M. E. M., Pace, L. E., Schwarz, E. B., & Ross‐Degnan, D. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.02.012 · Cited by 10
Testosterone, Athletic Context, Oral Contraceptive Use, and Competitive Persistence in Women
Casto, K., Arthur, L. C., Hamilton, D. K., & Edwards, D. A. (2021) · Adaptive Human Behavior and Physiology · doi:10.1007/s40750-021-00180-6 · Cited by 10
Lobysheva, I. I., Eeckhoudt, S. V., Zotti, F. D., Rifahi, A., Pothen, L., Beauloye, C., & Balligand, J. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.03.039 · Cited by 10
“The estrogenic component of CPs was shown to increase hepatic metabolism with higher production of lipoproteins and of procoagulant proteins depending on the potency of the estrogen; similar adverse effects proportional to the androgenicity of the progestins have been observed [15,16].”
BackgroundWeiserova, Z., Blahová, J., Dobukova, V., Maršálek, P., Hodkovicová, N., Lenz, J., Tichý, F., Franěk, R., Pšenička, M., Franc, A., et al. (2023) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2023.161911 · Cited by 9
Nomegestrol acetate/17-beta estradiol: a review of efficacy, safety, and patient acceptability
Akintomide, H., & Panicker, S. (2015) · Open Access Journal of Contraception · doi:10.2147/oajc.s61942 · Cited by 9
“32 No remarkable changes in the blood pressure measurements from baseline were observed in the two 1-year comparison studies conducted across Europe, Asia and Australia, 20 and the Americas 19 involving a total of 2,130 women who used NOMAC/E2.”
García-Beltrán, C., Peyrou, M., Navarro‐Gascon, A., López‐Bermejo, A., de Zegher, F., Villarroya, F., & Ibáñez, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1325230 · Cited by 8
“However, this approach has a limited capacity to improve metabolic status (3, 25, 26) and may cause sustained unfavorable changes in hepatic markers (25, 27).”
BackgroundMelhado‐Kimura, V., Alegre, S. M., Pavin, E. J., dos Santos, P. D. N. S., Bahamondes, L. G., & Fernandes, A. M. D. S. (2014) · The European Journal of Contraception & Reproductive Health Care · doi:10.3109/13625187.2014.961599 · Cited by 8
Oxidative Stress in Polycystic Ovary Syndrome: Impact of Combined Oral Contraceptives
Santander, N. G., Figueroa, E. G., González‐Candia, A., Maliqueo, M. A., Echiburú, B., Crisosto, N., & Salas‐Pérez, F. (2024) · Antioxidants · doi:10.3390/antiox13101168 · Cited by 8
Late Effects of Parasellar Lesion Treatment: Hypogonadism and Infertility
Sbardella, E., Minnetti, M., Pofi, R., Cozzolino, A., Greco, E., Gianfrilli, D., & Isidori, A. M. (2020) · Neuroendocrinology · doi:10.1159/000508107 · Cited by 8
Pannain, G. D., Rodrigues, V. D. O., Abreu, M., & Lima, G. B. (2022) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.1055/s-0041-1741410 · Cited by 8
“6 Even though both types of pills can inhibit follicle-stimulating hormone (FSH) and luteinizing hormone (LH) suf fi - ciently to prevent ovulation, the combined pills have greater antigonadotrophic and ovulation-inhibition effects.”
BackgroundSood, M., Zweig, S. B., Tolentino, M. C., Strizhevsky, M., & Poretsky, L. (2015) · Springer eBooks · doi:10.1007/978-3-319-20797-1_33-1 · Cited by 8
Taşkın, M. İ., Bilen, Ç., Ergün, A., Gençer, N., & Inceboz, U. S. (2015) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2015.03.014 · Cited by 8
“New progestins with high specificity have been designed to avoid interaction with other receptors and prevent androgenic, estrogenic, or glucocorticoid related side effects, and to prevent other undesirable side-effects especially on lipoproteins, clotting factors, and insulin sensitivity.(6) Cigarette smoking (CS) is…”
BackgroundA current perspective into young female sex hormone replacement: a review
Giordano Imbroll, M., & Gruppetta, M. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1816820 · Cited by 7
Metadata
- Authors
- Sitruk-Ware, R., & Nath, A.
- Affiliations
- Population Council (US)
- Corresponding author
- Sitruk-Ware, Regine
- Venue
- Best Practice & Research Clinical Endocrinology & Metabolism
- Publisher
- Elsevier BV
- Published
- 2013-02
- Volume
- 27
- Issue
- 1
- Pages
- 13-24
- ISSN
- 1521-690X (ISSN-L)
- OpenAlex
- W2101802759
- Cited by
- 247
- References
- 79
- Citations by year
- 2026: 14 · 2025: 17 · 2024: 23 · 2023: 45 · 2022: 18 · 2021: 24 · 2020: 22 · 2019: 19 · 2018: 9 · 2017: 12 · 2016: 12 · 2015: 12 · 2014: 17 · 2013: 3
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Best Practice & Research Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- oral contraceptives, ethinyl estradiol, progestins, hepatic metabolism, lipoproteins, insulin response, coagulation factors, cardiovascular risk, venous thromboembolism, contraceptive safety
- MeSH terms
- Contraceptives, Oral, Hormonal, Estrogens, Female, Humans, Progestins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review